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Abstract: Previously, we found fluoxetine reduces methamphetamine preference in mice. However, effects of fluoxetine 
on developed methamphetamine preference and on methamphetamine induced gene expression changes have been largely 
unknown. The present study investigates effects of post-treatment with fluoxetine on methamphetamine dependence and 
on gene expressions after long-term withdrawal in mice. First, we examined whether chronic post-treatment with fluoxet-
ine attenuated methamphetamine-conditioned place preference. Next, we examined the changes in gene expression levels 
after long-term withdrawal (with saline or fluoxetine treatment) following chronic methamphetamine treatment. Using 
mRNA from the pooled frontal cortices of 10 mice per group, gene expression analyses were performed using a custom-
developed cDNA array and a real-time quantitative reverse transcription-PCR. Chronic post-treatments with fluoxetine 
abolished the conditioned place preference developed by methamphetamine administrations. Even after long-term with-
drawal from repeated methamphetamine administration, -opioid receptor (MOP) gene expression was significantly re-
duced in the frontal cortex. The reduced MOP gene expression in the frontal cortex was restored by chronic administration 
with fluoxetine. These changes were confirmed by Western blot analyses. These findings suggest that the chronic post-
treatments with fluoxetine might be effective for restoring the reduction of MOP levels in the frontal cortex following 
long-term abstinence from methamphetamine. 
Keywords: Methamphetamine, conditioned place preference, gene expression, withdrawal, fluoxetine, mu-opioid receptor, 
frontal cortex, mice. 
INTRODUCTION 
  The development process of sensitization to the behav-
ioral effects of psychostimulants is well-researched. There is 
substantial evidence that the mesocorticolimbic dopamine 
system and its excitatory glutamatergic inputs are critical [1, 
2]. However, glutamate antagonists do not block the expres-
sion of sensitization [3]. Similarly, dopamine antagonists can 
block the development of sensitization to psychostimulants 
without blocking its expression [4]. On the other hand, glu-
tamatergic afferents from the prefrontal cortex to the ventral 
tegmental area and the nucleus accumbens have been report-
edly implicated in both the development and expression of 
sensitization to cocaine and amphetamine [5]. The frontal 
cortex is important region that is activated in addicted sub-
jects during intoxication, craving, and bingeing, and deacti-
vated during withdrawal [6]. 
  Currently, effective pharmacotherapy for psychostimu-
lant abuse has not been established. However, preclinical 
studies have indicated that the serotonergic system can effec-
tively modulate the behavioral effects of amphetamine. That  
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is, a negative relationship was observed between the poten-
cies of several cocaine- and amphetamine-like drugs in self-
administration studies and their binding affinities for sero-
tonin uptake sites [7, 8]. Administration of the serotonin up-
take inhibitor fluoxetine decreased self administration of 
amphetamine [9] in rodents. Amphetamine withdrawal ele-
vates brain reward threshold in rats [10]. Harrison et al. 
(2001) [11] have reported that co-administration of a 5-HT1A 
receptor antagonist and fluoxetine reverses reward deficits 
observed during nicotine or amphetamine withdrawal. These 
findings suggest that increasing brain serotonin activity can 
attenuate the behavioral and reinforcing effects of ampheta-
mines. 
  In the present study, we used the frontal cortices of 
chronically methamphetamine-injected mice to explore 
molecules that expressions were changed during long-term 
abstinence and fluoxetine reversed its expressional changes. 
First, we applied comprehensive approach to exploration of 
candidate genes by using cDNA array system utilizing 
mouse KIAA-homologous cDNA (mKIAA) clones. Next, 
gene expressions and protein expressions were examined by 
real-time quantitative reverse transcription-polymerase chain 
reaction (qRT-PCR) experiments and immunoblot analyses, 
respectively. 
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MATERIALS AND METHODS 
Animals 
  Ten-week-old male C57BL/6J mice were purchased from 
CLEA Japan (Tokyo, Japan). The experimental procedures 
and housing conditions were approved by the Tokyo Institute 
of Psychiatry Institutional Animal Care and Use Committee, 
and all animals were cared for and treated humanely in ac-
cordance with our institutional guidelines on animal experi-
mentation. 
Conditioned Place Preference Test 
  The conditioned place preference test was performed 
according to the method of Hoffman and Beninger (1988) 
[12] with some modifications. For this test, we used a two-
compartment Plexiglas chamber (Neuroscience Inc., Osaka, 
Japan). We selected a counterbalanced protocol to nullify 
each mouse’s initial compartment preference [13]. 
  Acquisition of methamphetamine-induce place prefer-
ence was shown in drug-naive mice. On Day 1, the mice (n = 
18 - 20 per group) were allowed to freely explore the two 
compartments for 15 min. On Day 2, the same trial was per-
formed, and the time spent in each compartment and shuttle 
numbers were measured for 15 min. Conditioning was con-
ducted once daily for four consecutive days (Days 5-8). Mice 
were intraperitoneally (i.p.) injected with methamphetamine 
(2 mg/kg) and immediately confined to the black or white 
compartment for 50 min on Day 5. On Day 6, the mice were 
injected with saline and immediately confined to the oppo-
site compartment for 50 min. On Days 7 and 8, the same 
conditioning as on Days 5 and 6 was repeated. After meth-
amphetamine conditioning, the mice received saline or 
fluoxetine (20 mg/kg, i.p.) once a day for 10 days (Days 9–
18). On the last day (Day 19), the mice were not treated with 
saline or fluoxetine. The time spent in each compartment and 
shuttle numbers were measured for 15 min without metham-
phetamine injection. Time spent in the drug-paired com-
partment during pre- and post-conditioning preference tests 
were analyzed by within-group paired t-tests. 
Tissue Preparation, RNA Isolation, Probe Labeling, and 
Microarray Hybridization 
  For analysis of gene expression studies, mice in the long-
term withdrawal groups were given a saline or metham-
phetamine injection (2 mg/kg, i.p.) once a day for 14 days, 
housed for 7 days without any injection, and then injected 
with saline or fluoxetine (20 mg/kg, i.p.) once a day for 14 
days and sacrificed 24 h after the last injection. 
  After decapitation, the frontal cortices from 10 mice per 
treatment group were quickly dissected on ice, immediately 
frozen at -80°C, and used as a pooled sample for the cDNA 
array experiment [14], qRT-PCR analysis and used as sepa-
rate samples for western blot analysis. 
qRT-PCR 
  To confirm the cDNA array results, qRT-PCR was per-
formed on the MOP gene using the TaqMan strategy 
(Mm01188089 m1) and the ABI Prism 7300 Sequence De-
tection System (Applied Biosystems, Foster City, CA). For 
the expression of the genes other than the MOP gene, real-
time qRT-PCR was performed using a cybergreen fluores-
cence-based assay kit (SBYR Green RT-PCR kit; Takara Bio 
Inc., Shiga, Japan) according to the manufacturer’s instruc-
tions. The levels of all cDNAs generated from mRNA by 
reverse transcription were calculated by the standard curve 
method for quantification and normalized with respect to 
GAPDH transcript levels. 
Western Blotting 
 P 2 membranes were prepared from homogenate derived 
from each frontal cortex. Samples were mixed with an equal 
volume of Laemmli's samples buffer (10 g/lane), boiled for 
3 min and then resolved on a 5-20% gradient SDS polyacry-
lamide gel electrophoresis. The proteins were electrotrans-
ferred onto PVDF membranes in a semi-dry blotter. 
  We used two rabbit polyclonal antibodies specific for 
MOP.  N-terminal-specific antiserum (N-38) was prepared 
against 1–38 amino acids sequences of the MOP N-terminus 
[15]. The C-terminus-specific antibody (AB5511, lot No. 
25050663) was purchased from Chemicon International 
(Temecula, CA, USA). Rabbit polyclonal anti-actin antibody 
was purchased from Sigma-Aldrich (St. Louis, MO, USA) 
and used to detect endogenous actin as an internal standard. 
Statistical Analysis 
  Parametric analysis of quantitative data was performed 
using a one-way analysis of variance (ANOVA) followed by 
Scheffe's test. Nonparametric analysis was conducted using 
the Kruskal-Wallis test followed by Scheffe's post hoc  
comparison test. The level of statistical significance was set 
at p < 0.05. 
RESULTS 
Effects of Chronic Administration of Fluoxetine on 
Methamphetamine-Induced Conditioned Place Prefer-
ence 
  Time spent in the conditioned compartment was signifi-
cantly increased when saline was administered for 9 days 
after methamphetamine conditioning (n = 20, t = 4.408, p = 
0.0003; Fig. (1A)). By contrast, time spent in the conditioned 
compartment was not significantly changed when fluoxetine 
(20 mg/kg) was administered for 9 days after methampheta-
mine conditioning (n = 18, t = 1.513, p = 0.1488; Fig. (1B)). 
These results suggest that subchronic administration of 
fluoxetine at a dose of 20 mg/kg to mice weakened the place 
preference induced by methamphetamine. Thus next, we 
used mice chronically treated with fluoxetine (20 mg/kg) 
during methamphetamine withdrawal in the gene expression 
and western blot analyses. 
Effects of Fluoxetine on Methamphetamine-Induced 
Changes in Gene Expression after Long-Term With-
drawal 
  In the cDNA array experiments, expressions of a few 
genes, MOP, N-methyl-D-aspartate (NMDA) receptor 2D 
subunit (NR2D), nociceptin receptor, G protein-activated 
inwardly rectifying K
+ channels (GIRKs) and inward recti-
fier K
+ channel Kir2.3 (IRK3), were reduced after 3 weeks 
withdrawal following chronic methamphetamine treatment 
(MAP-Saline column in Table 1). These reductions (< 70 % MOP Reduction During Long-Term Methamphetamine Withdrawal  Current Neuropharmacology, 2011, Vol. 9, No. 1    75 
reduction in the saline treatment) were recovered in some 
genes except GIRK1 and GIRK3 when treated with fluoxet-
ine for 2 weeks after the chronic methamphetamine treat-
ment (MAP-Flx in Table 1). The cDNA array experiments 
were performed in multiple determinations using a set of 
pooled samples. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Effects of chronic administration of fluoxetine on the es-
tablished methamphetamine-induced conditioned place preference. 
After methamphetamine conditioning, mice received (A) saline or 
(B) fluoxetine for 9 days. Each bar represents mean ± SEM of the 
time spent in the methamphetamine-paired compartment during a 
15-min test session. Pre: preference test during the pre-conditioning 
phase. Post: preference test during the post-conditioning phase. 
***: difference between Pre and Post, p < 0.001. 
  To assess data derived from cDNA array, we performed 
qRT-PCR analyses on these gene expressions using mRNA 
derived from three sets of pooled cortices. The qRT-PCR 
data were shown in parenthesis in Table 1. Expressions of 
mu-opioid receptor and IRK3 were approximately similar 
between cDNA array and qRT-PCR analyses. However, 
gene expressions of NR2D, nociceptin receptor and GIRK2 
were not reduced after 3 weeks withdrawal following 
chronic methamphetamine treatment (parenthesis of MAP-
Saline column in Table 1). On the other hand, reduced ex-
pression (MAP-Saline) of mu-opioid receptor was recovered 
by fluoxetine treatment til 93%, while that of IRK3 was 35% 
(parenthesis of % recovery by fluoxetine treatment in Table 1). 
  Results using cDNA array experiment and qRT-PCR 
analyses had shown that the reduced gene expression of 
MOP in the frontal cortex during long-term withdrawal was 
restored by subsequent fluoxetine treatments. 
Fluoxetine Effects on MOP-Immunoreactivity 
  To investigate the results obtained from the gene expres-
sion analyses, immunoblot of MOP in each frontal cortex of 
methamphetamine-injected mouse was performed (4 – 12 
mice per group). MOP-immunoreactivity (IR) in the frontal 
cortex was detected as a broad band at a position consistent 
with a molecular weight of 65,000 with anti-MOP sera (N-38 
and AB5511) (Fig. (2A)). These two anti-MOP sera (N-38 
and AB5511) were specific against MOP molecule. The de-
tected broad bands by these antisera were abolished using 
MOP knockout mice. MOP-IR with AB5511 antibody of the 
MAP-Saline sample (3-week withdrawal with saline injec-
tions after chronic methamphetamine injections, n = 11) was 
significantly lower than that of the Saline-Saline sample (3-
week withdrawal with saline injections after chronic saline 
injections, n = 12) (p = 0.0101; Fig. (2B)). The intensity of 
MOP-IR in the MAP-Flx sample (3-week withdrawal with 
fluoxetine injections after chronic methamphetamine injec-
tions, n = 4) was significantly higher than that in the MAP-
Saline sample (p = 0.0203; Fig. (2B)) and not different from 
that in the Saline-Saline sample (p = 0.902). The intensity of 
MOP-IR in the Saline-Flx sample (3-week withdrawal with 
fluoxetine injections after chronic saline injections, n = 6) 
was not significantly different from those in the Saline-
Saline and MAP-Flx samples (p = 0.699; p = 0.473). These 
results have shown that MOP-IR was reduced after 3 weeks 
withdrawal following chronic methamphetamine treatment 
and this reduction was recovered by subsequent fluoxetine 
treatments. 
DISCUSSION 
  In the present study, repeated methamphetamine 
administration induced a conditioned place preference. The 
place preference was significantly attenuated by chronic 
fluoxetine treatments during long-term withdrawal. 
Fluoxetine is reported to reverse reward deficits during 
amphetamine withdrawal [11]. Recently, Kaneko et al. 
(2007) [16] reported that 5-day treatment with fluoxetine and 
paroxetine during methamphetamine withdrawal may at least 
in part reverse methamphetamine-induced behavioral 
sensitization. Taken together, these results suggest that 
chronic fluoxetine treatment can partially reverse 
methamphetamine-induced behavioral changes. 
  We observed that 3-week withdrawal after chronic meth-
amphetamine induced gene expression changes. Of interest, 
both in the cDNA array and the real-time qRT-PCR analy-
ses, MOP gene expression was decreased in the frontal cor-
tex after long-term withdrawal, and partially restored by 
chronic fluoxetine treatment during methamphetamine with-
drawal. On the basis of these results of gene expressions, we 
have performed the protein expressions of MOP by western 
blot analysis. Of interest, immunoreactive MOP level was 
significantly reduced during methamphetamine withdrawal, 
while chronic fluoxetine administrations during withdrawal 
could partially restore the reduced MOP expression level in 
the frontal cortex. 
  To date, changes in MOP expression after withdrawal 
from alcohol and amphetamine have been reported. Lower 
MOP binding potential in the right dorsal lateral prefrontal 
cortex, the right anterior frontal cortex, and the right parietal 
cortex is associated with higher craving in male alcohol-
dependent subjects undergoing alcohol withdrawal [17], 
even though after long-term abstinence alcoholic patients 
display no changes in the prefrontal cortex but an increase in 
the binding potential of MOP in the ventral striatum, includ-
ing the nucleus accumbens [18]. In contrast, subchronic   
injections of amphetamine resulted in a significant reduction 
in MOP mRNA levels in the nucleus accumbens shell [19], 
whereas no significant changes were observed in the level of 
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Table 1.  Effect of Chronic Fluoxetine Treatment on Changes in Gene Expression After Long-Term Withdrawal Following Chronic 
Methamphetamine Injections 
cDNA Array Result (RT-PCR Result) 
                    Entrez  Gene(Property) MAP-Saline  MAP-Flx Saline-Flx  %  of  Recovery 
Official 
Symbol Gene  ID 
(% of Saline-
Saline Control)   
by Flx  
Treatment 
                                       Receptors 
Htr2c 15560  5HTR1C  88.5  78.3  88.9 
Htr1e 107927  5HTR1E  94.8  85.5  107.6 
Htr2a 15558  5HTR2A  108.3  102.6  113.1 
Adra2a 11551  alpha2AR  115.5  93.8  97.5 
Bzrap1  207777  benzodiazapine receptor (peripheral) associated protein 1  88.0  90.0  82.4 
Oprd1 18386  delta-opioid  receptor  74.2  90.0  90.0 
Esrrg 26381  estrogen-related  receptor  gamma  80.4  74.6  83.4 
Oprk1 18387  kappa-opioid  receptor  80.4  101.8  115.1 
Lepr 16847  leptin  R  95.8  90.7  99.3 
Sigmar1 18391 Sigma-1  receptor  87.9  83.4  96.5 
Oprm1  18390  mu-opioid receptor  58.5 (75.0)  83.4 (98.2)  86.4 (90.1) 
Grm1 14816  mGluR1  105.0  117.5  120.5 
Grm5 108071  mGluR5  84.3  82.6  98.7 
Npy2r 18167  neuropeptideY-Y2  receptor  93.4  93.2  84.5 
Grin2b 14812  NR2B  70.1  78.0  96.1 
Grin2c 14813  NR2C  85.9  79.7  92.3 
 
 
 
 
 
 
60.0 (92.8) 
Grin2d  14814  NR2D  60.8 (95.3)  64.5 (80.7)  84.2 (88.2) 
Grin1 14810  NR1  88.9  104.8  95.7 
9.4 
Oprl1  18389  nociceptin receptor  68.8 (102)  91.1 (92.2)  81.5 (92.4) 
Ogfr  72075  opioid growth factor receptor  94.2  105.9  112.7 
71.6 
                                      Ion Channels 
Cacna2d2  56808  calcium channel, voltage-dependent,  86.4  103.2  90.8 
Kcnj3 16519  GIRK1  63.4  54.4  70.9 
Kcnj6  16522  GIRK2  66.1 (92.5)  79.0 (106)  78.7 (98.3) 
Kcnj9 16524  GIRK3  57.5  54.4  71.9 
Kcnj12 16515  IRK2  72.3  102.0  96.1 
38.2 
Kcnj4  16520  IRK3  63.7 (67.3)  76.4 (78.8)  93.1 (70.8) 
Kcns2 16539  K
+ voltage-gated channel, subfamily S, 2  112.3  123.9  122.9 
Rims3 242662 
K
+ channel, subfamily K, member 15 and regulating 
synaptic membrane exocytosis 3  95.0 95.9 123.6 
Kcnt1 227632  K
+ channel, subfamily T, member 1  83.1  95.8  80.2 
Kcnd2 16508  K
+ voltage-gated channel, Shal-related subfamily  76.3  83.5  97.2 
Scn3b 235281  Na
+ channel, voltage-gated, type III, beta  90.5  94.5  99.3 
34.8 
The qRT-PCR data were shown in parenthesis in Table 1. 
Treatment for 2 weeks with saline followed by two weeks with saline (Saline-Saline); treatment for 2 weeks with methamphetamine followed by 2 weeks with saline (MAP-Saline); 
treatment for 2 weeks with methamphetamine followed by 2 weeks with fluoxetine (MAP-Flx); and treatment for 2 weeks with saline followed by 2 weeks with fluoxetine (Saline-
Flx). 
Data are presented as percentages of Saline-Saline group, representing the mean ± SEM of 4-16 determinations of pooled samples. 
Percentage of recovery was calculated as follows: (1-[(100-[MAP-Flx]value) / (100-[MAP-Saline]value)]) x 100. MOP Reduction During Long-Term Methamphetamine Withdrawal  Current Neuropharmacology, 2011, Vol. 9, No. 1    77 
 
MOP mRNA expressed in the nucleus accumbens shell of 
behaviorally sensitized rats tested 2 or 14 days after with-
drawal [20]. Recently, Chiu et al. (2006) [21] have used the 
whole brain except cerebellum repeatedly injected with 2.5 
mg/kg of methamphetamine for 7 days and reported that 
maximal binding of MOP is not changed on days 2 and 5, 
but down-regulated on day 8. After cessation of drug treat-
ments, the maximal binding of MOP returns to normal level 
on day 11 and up-regulates on day 21. These data are of in-
terest considering that the expressions of behavioral sensiti-
zation were attenuated by pretreatment with 10 or 20 mg/kg 
of naltrexone either during the induction period or before 
methamphetamine challenge when they were tested on days 
11 and 21 [22]. However they also mention that whole brain 
samples may be insufficient to reveal the region-specific 
changes [21]. Investigating methamphetamine-induced crav-
ing, endogenous opioid system is involved in the mecha-
nisms underlying cue-induced relapse [23]. Naltrexone in-
hibits reinstatement of drug-seeking behavior induced by 
methamphetamine-associated cues, but has no effect on 
methamphetamine-priming-induced reinstatement. The im-
plication of these results is that there are distinct mechanisms 
underlying drug-seeking behavior induced by re-exposure to 
drug-associated cues and that induced by drug priming. Fur-
ther, the results indicate that increasing activity of the opioid 
system is involved in the cue-induced drug-seeking behavior, 
but not in that induced by drug-priming [23]. Naltrexone 
pretreatment also attenuates context-induced alcohol seeking 
and inhibits c-fos mRNA expression in the basolateral 
amygdala and the CA3 subregion of the hippocampus [24]. 
Therefore, regional specificity is important to study meth-
amphetamine induced behaviors, including conditioned place 
preference, drug-seeking behavior and behavioral sensitiza-
tion. To our knowledge, this is the first report of reduced 
MOP expression in the frontal cortex of long-term metham-
phetamine withdrawal detected by gene expression and   
protein expression analyses. This result would provide   
important insight into the relationship between mu-opioid 
receptor in the frontal cortex and methamphetamine induced 
behaviors. 
  In humans, Ide et al. (2006) [25] have shown associations 
between MOP gene (OPRM1) polymorphisms and metham-
phetamine dependence/psychosis. They also found signifi-
cant differences in both genotype and allele frequencies of 
single-nucleotide polymorphisms (SNPs) in the OPRM1 gene 
between control and methamphetamine-dependent/psychotic 
patients. There also is a significant association between 
SNPs and patients with transient psychosis. These findings 
suggest that MOP function may affect the development of 
methamphetamine psychosis. MOP also may be a key mole-
cule involved in the mechanisms underlying behavioral 
changes after long-term withdrawal following chronic meth-
amphetamine treatment. 
  In conclusion, the present study showed that reduced 
mRNA and protein expressions of MOP gene were found in 
the frontal cortex of methamphetamine-abuse model mice 
even after long-term abstinence. Furthermore, the subchronic 
fluoxetine treatment during methamphetamine withdrawal 
restored MOP expressions. Although the mechanisms under-
lying the therapeutic effect of fluoxetine for methampheta-
mine abuse should be further investigated, we suggest a pos-
sibility that the restoration of MOP expression can be used as 
one of therapeutic markers for drug dependence. 
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Fig. (2). Immunoblot analyses of changes in MOP protein levels in 
the frontal cortex by saline or methamphetamine treatment followed 
by saline or fluoxetine treatment. (A) Typical immunoblot with 
anti-MOP and anti-actin antibodies. Using antiserum selective for 
MOP  N-terminal (N-38) or C-terminal (AB5511), similar broad 
bands were detected using the same membrane. Actin levels were 
measured as references. (B) Quantitation of densitometer values 
using antiserum (AB5511). Values were normalized using actin 
values and represented as percentage of saline control values. Each 
bar represents the mean ± SEM of more than four individual mouse 
frontal cortices. Treatment for 2 weeks with saline followed by two 
weeks with saline (saline-saline [SS] sample, n = 12); treatment for 
2 weeks with methamphetamine followed by 2 weeks with saline 
(methamphetamine-saline [MS] sample, n = 11); treatment for 2 
weeks with methamphetamine followed by 2 weeks with fluoxetine 
(methamphetamine-fluoxetine [MF] sample, n = 4); and treatment 
for 2 weeks with saline followed by 2 weeks with fluoxetine (sa-
line-fluoxetine [SF] sample, n = 6). *: difference between metham-
phetamine-saline group and saline-saline group or methampheta-
mine-fluoxetine group, p < 0.05, ANOVA. 
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